We focus on not only treating disease but also enhancing quality of life.
Focus on discovery of novel drugs to address unmet medical needs
Using the Greater China Operation Platform as a springboard to global markets
March 22, 2023
TaiGen Enters Exclusive License Agreement with Joincare for TG-1000
August 28, 2022
TaiGen Nemonoxacin Granted Marketing Authorization in Russia
March 31, 2020
R&D
Overcoming antibiotic resistance and other areas of high unmet medical need.
SEE MORE
February 25, 2020
About Us
A discovery-based and market-focused pharmaceutical company with experience in anti-infectives.
SEE MORE
April 9, 2020
Investors
Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
SEE MORE
April 9, 2020
ESG
Society provides, so we give back to society. We operate in ways that enhance society and the environment, instead of contributing negatively to them.
SEE MORE